Related Experiment Video
Updated: May 14, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
Biomaterial-based strategies for postoperative residual tumors: From margin clearance to immune control and tissue
Meiyan Zou1, Xu Chen1, Nina Li1
1Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, Guangdong, 510280, China.
Abstract:
Postoperative and post-ablation residual tumors represent a major yet underrecognized source of cancer recurrence, metastasis, and therapeutic failure. Distinct from primary tumors, residual lesions are typically sparse, spatially dispersed, and embedded within dynamically evolving microenvironments shaped by wound healing, inflammation, hypoxia, and immune imbalance. These features create pronounced spatiotemporal blind spots that limit the effectiveness of conventional systemic therapies and necessitate treatment strategies capable of precise local intervention, coordinated multimodal action, and active microenvironmental reconstruction. This review examines recent advances in nanomaterial-based approaches for the management of postoperative residual tumors, encompassing intraoperative and early postoperative nanotechnologies for high-resolution margin visualization and immediate disease clearance, as well as localized and sustained delivery systems-including hydrogels, implantable scaffolds, and microenvironment-responsive nanoparticles-that overcome spatial inaccessibility and temporal mismatch through prolonged retention and controlled activation. Multifunctional nanoplatforms integrating physical ablation, chemical or metabolic intervention, immune modulation, and tissue-supportive architectures are further highlighted for their ability to induce immunogenic cell death, remodel immunosuppressive niches, and concurrently promote postoperative tissue repair and functional recovery. Key challenges limiting clinical translation, including long-term biosafety, residual tumor heterogeneity, incomplete mechanistic resolution of immune effects, and the lack of standardized evaluation frameworks, are also discussed. By framing residual tumors as a coupled problem of tumor eradication and postoperative microenvironmental reconstruction, this review provides a unified conceptual framework to guide the rational design of nanomaterials for durable control of residual disease.
Insights
Nanomaterials offer new ways to manage residual tumors after surgery or ablation, improving cancer treatment outcomes. These advanced therapies target remaining cancer cells and reconstruct the tumor microenvironment for better results.
Area of Science:
- Oncology
- Nanotechnology
- Biomaterials
Background:
- Postoperative and post-ablation residual tumors are a significant cause of cancer recurrence and treatment failure.
- These tumors present unique challenges due to their sparse, dispersed nature and dynamic microenvironments.
- Conventional therapies are often ineffective against residual disease.
Purpose of the Study:
- To review recent advances in nanomaterial-based strategies for managing postoperative residual tumors.
- To highlight nanotechnologies for intraoperative margin visualization, disease clearance, and localized drug delivery.
- To discuss multifunctional nanoplatforms for combined tumor eradication and microenvironment remodeling.
Main Methods:
- Review of current literature on nanomaterial applications in residual tumor management.
- Analysis of intraoperative and early postoperative nanotechnologies.
- Examination of localized and sustained drug delivery systems (hydrogels, scaffolds, nanoparticles).
- Discussion of multifunctional nanoplatforms integrating physical, chemical, and immunological approaches.
Main Results:
- Nanomaterials enable high-resolution margin visualization and immediate disease clearance.
- Localized delivery systems overcome spatial and temporal challenges for sustained treatment.
- Multifunctional nanoplatforms can induce immunogenic cell death and remodel immunosuppressive niches.
- Nanomaterials promote tissue repair and functional recovery post-surgery.
Conclusions:
- Nanomaterial-based approaches offer a promising framework for durable control of residual tumors.
- Addressing residual tumors requires a combined strategy of tumor eradication and microenvironment reconstruction.
- Further research is needed to overcome challenges in clinical translation, including biosafety and standardization.
Related Concept Videos
The Tumor Microenvironment
Tumor Immunotherapy
